Active, not recruitingPHASE1, PHASE2NCT04881032

AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma

Studying Glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Centre Jean Perrin
Principal Investigator
Juliette Moreau, Md
Centre Jean Perrin
Intervention
Polysiloxane Gd-Chelates based nanoparticles (AGuIX)(drug)
Enrollment
66 enrolled
Eligibility
18-75 years · All sexes
Timeline
20222027

Study locations (9)

Collaborators

Ministry for Health and Solidarity, France

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04881032 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma

← Back to all trials